MRKR
Price:
$3.38
Market Cap:
$30.16M
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and...[Read more]
Industry
Biotechnology
IPO Date
2002-07-16
Stock Exchange
NASDAQ
Ticker
MRKR
According to Marker Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.16. This represents a change of -25.43% compared to the average of -4.24 of the last 4 quarters.
The mean historical PE Ratio of Marker Therapeutics, Inc. over the last ten years is -3.07. The current -3.16 PE Ratio has changed 10.20% with respect to the historical average. Over the past ten years (40 quarters), MRKR's PE Ratio was at its highest in in the October 2015 quarter at 2.93. The PE Ratio was at its lowest in in the June 2019 quarter at -16.48.
Average
-3.07
Median
-2.06
Minimum
-10.89
Maximum
-0.14
Discovering the peaks and valleys of Marker Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.31%
Maximum Annual PE Ratio = -0.14
Minimum Annual Increase = -78.78%
Minimum Annual PE Ratio = -10.89
Year | PE Ratio | Change |
---|---|---|
2023 | -3.45 | 364.73% |
2022 | -0.74 | -57.25% |
2021 | -1.74 | -27.39% |
2020 | -2.39 | -62.98% |
2019 | -6.46 | 801.90% |
2018 | -0.72 | -78.78% |
2017 | -3.37 | -69.01% |
2016 | -10.89 | 1.31% |
2015 | -0.77 | 452.03% |
2014 | -0.14 | -65.86% |
The current PE Ratio of Marker Therapeutics, Inc. (MRKR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-1.98
5-year avg
-2.96
10-year avg
-3.07
Marker Therapeutics, Inc.’s PE Ratio is less than Lumos Pharma, Inc. (-1.04), greater than Exicure, Inc. (-8.14), less than Protagenic Therapeutics, Inc. (-0.39), less than PMV Pharmaceuticals, Inc. (-1.47), greater than Anebulo Pharmaceuticals, Inc. (-5.30), greater than Miromatrix Medical Inc. (-7.13), greater than ZIVO Bioscience, Inc. (-5.50), less than Bionomics Limited (-0.30), less than Agenus Inc. (-0.26), greater than Icosavax, Inc. (-15.78), less than Galera Therapeutics, Inc. (-0.08), greater than Edgewise Therapeutics, Inc. (-22.36), greater than RenovoRx, Inc. (-3.51), less than Tempest Therapeutics, Inc. (-0.62), less than Ikena Oncology, Inc. (-1.24), greater than Catalyst Biosciences, Inc. (-28.21), less than Acrivon Therapeutics, Inc. Common Stock (-3.08), less than Alector, Inc. (-1.13), less than Aadi Bioscience, Inc. (-1.32), greater than Keros Therapeutics, Inc. (-3.32), less than Aerovate Therapeutics, Inc. (-0.89),
Company | PE Ratio | Market cap |
---|---|---|
-1.04 | $37.54M | |
-8.14 | $44.77M | |
-0.39 | $3.34M | |
-1.47 | $76.07M | |
-5.30 | $42.01M | |
-7.13 | $92.95M | |
-5.50 | $78.37M | |
-0.30 | $789.08M | |
-0.26 | $64.51M | |
-15.78 | $769.04M | |
-0.08 | $1.63M | |
-22.36 | $2.80B | |
-3.51 | $30.96M | |
-0.62 | $37.39M | |
-1.24 | $73.83M | |
-28.21 | $19.42M | |
-3.08 | $193.98M | |
-1.13 | $181.18M | |
-1.32 | $73.94M | |
-3.32 | $676.88M | |
-0.89 | $75.07M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Marker Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Marker Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Marker Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Marker Therapeutics, Inc. (MRKR)?
What is the highest PE Ratio for Marker Therapeutics, Inc. (MRKR)?
What is the 3-year average PE Ratio for Marker Therapeutics, Inc. (MRKR)?
What is the 5-year average PE Ratio for Marker Therapeutics, Inc. (MRKR)?
How does the current PE Ratio for Marker Therapeutics, Inc. (MRKR) compare to its historical average?